Expanded allogeneic adipose-derived mesenchymal stem cells (Cx601) for complex perianal fistulas in Crohn's disease: a phase 3 randomised, double-blind controlled trial

医学 安慰剂 克罗恩病 临床终点 外科 人口 耐火材料(行星科学) 内科学 临床试验 胃肠病学 疾病 病理 天体生物学 环境卫生 物理 替代医学
作者
Julián Panés,Damián García‐Olmo,Gert Van Assche,Jean‐Frédéric Colombel,Walter Reinisch,Daniel C. Baumgart,Axel U Dignass,Maria Nachury,Marc Ferrante,Lili Kazemi-Shirazi,Jean Charles Grimaud,Fernando de la Portilla,Eran Goldin,Marie Paule Richard,Anne Leselbaum,Silvio Danese
出处
期刊:The Lancet [Elsevier BV]
卷期号:388 (10051): 1281-1290 被引量:1210
标识
DOI:10.1016/s0140-6736(16)31203-x
摘要

Background Complex perianal fistulas in Crohn's disease are challenging to treat. Allogeneic, expanded, adipose-derived stem cells (Cx601) are a promising new therapeutic approach. We aimed to assess the safety and efficacy of Cx601 for treatment-refractory complex perianal fistulas in patients with Crohn's disease. Methods We did this randomised, double-blind, parallel-group, placebo-controlled study at 49 hospitals in seven European countries and Israel from July 6, 2012, to July 27, 2015. Adult patients (≥18 years) with Crohn's disease and treatment-refractory, draining complex perianal fistulas were randomly assigned (1:1) using a pre-established randomisation list to a single intralesional injection of 120 million Cx601 cells or 24 mL saline solution (placebo), with stratification according to concomitant baseline treatment. Treatment was administered by an unmasked surgeon, with a masked gastroenterologist and radiologist assessing the therapeutic effect. The primary endpoint was combined remission at week 24 (ie, clinical assessment of closure of all treated external openings that were draining at baseline, and absence of collections >2 cm of the treated perianal fistulas confirmed by masked central MRI). Efficacy was assessed in the intention-to-treat (ITT) and modified ITT populations; safety was assessed in the safety population. This study is registered with ClinicalTrials.gov, number NCT01541579. Findings 212 patients were randomly assigned: 107 to Cx601 and 105 to placebo. A significantly greater proportion of patients treated with Cx601 versus placebo achieved combined remission in the ITT (53 of 107 [50%] vs 36 of 105 [34%]; difference 15·2%, 97·5% CI 0·2–30·3; p=0·024) and modified ITT populations (53 of 103 [51%] vs 36 of 101 [36%]; 15·8%, 0·5–31·2; p=0·021). 18 (17%) of 103 patients in the Cx601 group versus 30 (29%) of 103 in the placebo group experienced treatment-related adverse events, the most common of which were anal abscess (six in the Cx601 group vs nine in the placebo group) and proctalgia (five vs nine). Interpretation Cx601 is an effective and safe treatment for complex perianal fistulas in patients with Crohn's disease who did not respond to conventional or biological treatments, or both. Funding TiGenix.
最长约 10秒,即可获得该文献文件

科研通智能强力驱动
Strongly Powered by AbleSci AI
科研通是完全免费的文献互助平台,具备全网最快的应助速度,最高的求助完成率。 对每一个文献求助,科研通都将尽心尽力,给求助人一个满意的交代。
实时播报
刚刚
Owen的应助被爱听歌的寄云采纳,获得10
1秒前
lyn完成签到,获得积分10
1秒前
2秒前
晚风发布了新的文献求助10
2秒前
shuangquan完成签到 ,获得积分10
2秒前
Nicu发布了新的文献求助10
3秒前
4秒前
元吉的应助被谨慎的月亮采纳,获得10
4秒前
JM完成签到,获得积分10
4秒前
ghost完成签到 ,获得积分10
4秒前
4秒前
YYT发布了新的文献求助10
5秒前
5秒前
5秒前
慕青的应助被咕噜圈儿采纳,获得10
5秒前
zs发布了新的文献求助10
6秒前
核桃发布了新的文献求助10
7秒前
哞哞发布了新的文献求助10
7秒前
俭朴的明轩完成签到,获得积分10
8秒前
胡大叔发布了新的文献求助10
9秒前
10秒前
顺心秋凌发布了新的文献求助10
10秒前
文艺代灵发布了新的文献求助10
10秒前
ezekiet发布了新的文献求助10
10秒前
sep完成签到 ,获得积分10
10秒前
酷波er的应助被YYT采纳,获得10
10秒前
gww完成签到,获得积分20
10秒前
11秒前
11秒前
13秒前
斯文败类的应助被科研通管家采纳,获得30
13秒前
13秒前
zxp的应助被科研通管家采纳,获得30
14秒前
十二完成签到 ,获得积分10
14秒前
赘婿的应助被科研通管家采纳,获得10
14秒前
充电宝的应助被科研通管家采纳,获得10
14秒前
bkagyin的应助被科研通管家采纳,获得10
14秒前
14秒前
Jasper的应助被科研通管家采纳,获得10
14秒前
高分求助中
(应助此贴封号)【重要!!请各用户(尤其是新用户)详细阅读】【科研通的精品贴汇总】 10000
拉伸高分子熔体中缠结行为的模拟和小角中子散射研究 1700
Grapes 1000
The World Atlas of Wine 9th edition 1000
奈特基础组织学:配套组织病理学(第4版)(Netter's Essential Histology With Correlated Histopathology) 800
John McDowells Bildungstheorie 800
八旗制度の研究 600
热门求助领域 (近24小时)
化学 材料科学 医学 生物 纳米技术 计算机科学 工程类 有机化学 化学工程 生物化学 物理 复合材料 内科学 催化作用 光电子学 人工智能 细胞生物学 无机化学 物理化学 数学
热门帖子
关注 科研通微信公众号,转发送积分 8178807
求助须知:如何正确求助?哪些是违规求助? 9569558
关于积分的说明 21805222
捐赠科研通 7773974
什么是DOI,文献DOI怎么找? 3432933
关于科研通互助平台的介绍 2556873
邀请新用户注册赠送积分活动 2478593